CHICAGO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new data from the Phase III ARIES studies evaluating ambrisentan in patients with pulmonary arterial hypertension (PAH) at CHEST 2007, the annual meeting of the American College of Chest Physicians, taking place in Chicago, Illinois, October 20-25. Ambrisentan is an ETA-selective endothelin receptor antagonist (ERA) that was recently granted accelerated approval under the tradename LetairisTM (ambrisentan 5 mg and 10 mg tablets) by the U.S. Food and Drug Administration (FDA). Letairis is indicated as a once-daily treatment for PAH (WHO Group 1) in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening.
